Combined Use of Cabozantinib and Nivolumab in Clinical Practice
Introduction. The present article discusses renal cancer, one of the common malignant diseases. Historical and modern therapies are considered, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The results of clinical studies evaluating the efficacy of combined drug therapy are...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2024-04-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850050303784648704 |
|---|---|
| author | V. E. Askarov A. V. Sultanbaev K. V. Menshikov Sh. I. Musin N. I. Sultanbaeva E. V. Popova I. A. Menshikova |
| author_facet | V. E. Askarov A. V. Sultanbaev K. V. Menshikov Sh. I. Musin N. I. Sultanbaeva E. V. Popova I. A. Menshikova |
| author_sort | V. E. Askarov |
| collection | DOAJ |
| description | Introduction. The present article discusses renal cancer, one of the common malignant diseases. Historical and modern therapies are considered, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The results of clinical studies evaluating the efficacy of combined drug therapy are discussed, including the combination of immune checkpoint inhibitors with angiogenesis of targeted therapy.Materials and methods. A case is presented of a patient with metastatic clear cell renal cell carcinoma with multiple lung metastases. The diagnosis was established using computed tomography data and was not verified. Various therapy regimens were used during treatment, including pazopanib, nivolumab, and the combination of nivolumab with cabozantinib.Results and discussion. Follow-up examinations showed disease stabilization and normal tolerance of therapy. Eventually, the patient underwent laparoscopic cytoreductive nephrectomy. The therapy with nivolumab in combination with cabozantinib is still ongoing.Conclusion. The combined use of cabozantinib and nivolumab currently constitutes a promising strategy for treating renal cell cancer, in which cabozantinib prevents tumor progression, and nivolumab increases immune system activity, promoting tumor cell destruction. |
| format | Article |
| id | doaj-art-ed225af4863d4075987381b209a6c8a1 |
| institution | DOAJ |
| issn | 2076-3093 2307-0501 |
| language | English |
| publishDate | 2024-04-01 |
| publisher | Bashkir State Medical University |
| record_format | Article |
| series | Креативная хирургия и онкология |
| spelling | doaj-art-ed225af4863d4075987381b209a6c8a12025-08-20T02:53:30ZengBashkir State Medical UniversityКреативная хирургия и онкология2076-30932307-05012024-04-011419410010.24060/2076-3093-2024-14-1-94-100568Combined Use of Cabozantinib and Nivolumab in Clinical PracticeV. E. Askarov0A. V. Sultanbaev1K. V. Menshikov2Sh. I. Musin3N. I. Sultanbaeva4E. V. Popova5I. A. Menshikova6Republican Clinical Oncology DispensaryRepublican Clinical Oncology DispensaryRepublican Clinical Oncology Dispensary; Bashkir State Medical UniversityRepublican Clinical Oncology DispensaryRepublican Clinical Oncology DispensaryRepublican Clinical Oncology DispensaryBashkir State Medical UniversityIntroduction. The present article discusses renal cancer, one of the common malignant diseases. Historical and modern therapies are considered, including tyrosine kinase inhibitors and immune checkpoint inhibitors. The results of clinical studies evaluating the efficacy of combined drug therapy are discussed, including the combination of immune checkpoint inhibitors with angiogenesis of targeted therapy.Materials and methods. A case is presented of a patient with metastatic clear cell renal cell carcinoma with multiple lung metastases. The diagnosis was established using computed tomography data and was not verified. Various therapy regimens were used during treatment, including pazopanib, nivolumab, and the combination of nivolumab with cabozantinib.Results and discussion. Follow-up examinations showed disease stabilization and normal tolerance of therapy. Eventually, the patient underwent laparoscopic cytoreductive nephrectomy. The therapy with nivolumab in combination with cabozantinib is still ongoing.Conclusion. The combined use of cabozantinib and nivolumab currently constitutes a promising strategy for treating renal cell cancer, in which cabozantinib prevents tumor progression, and nivolumab increases immune system activity, promoting tumor cell destruction.https://www.surgonco.ru/jour/article/view/921renal cell cancercabozantinibnivolumabchemotherapyimmunotherapytyrosine kinase inhibitorsvascular endothelial growth factor |
| spellingShingle | V. E. Askarov A. V. Sultanbaev K. V. Menshikov Sh. I. Musin N. I. Sultanbaeva E. V. Popova I. A. Menshikova Combined Use of Cabozantinib and Nivolumab in Clinical Practice Креативная хирургия и онкология renal cell cancer cabozantinib nivolumab chemotherapy immunotherapy tyrosine kinase inhibitors vascular endothelial growth factor |
| title | Combined Use of Cabozantinib and Nivolumab in Clinical Practice |
| title_full | Combined Use of Cabozantinib and Nivolumab in Clinical Practice |
| title_fullStr | Combined Use of Cabozantinib and Nivolumab in Clinical Practice |
| title_full_unstemmed | Combined Use of Cabozantinib and Nivolumab in Clinical Practice |
| title_short | Combined Use of Cabozantinib and Nivolumab in Clinical Practice |
| title_sort | combined use of cabozantinib and nivolumab in clinical practice |
| topic | renal cell cancer cabozantinib nivolumab chemotherapy immunotherapy tyrosine kinase inhibitors vascular endothelial growth factor |
| url | https://www.surgonco.ru/jour/article/view/921 |
| work_keys_str_mv | AT veaskarov combineduseofcabozantinibandnivolumabinclinicalpractice AT avsultanbaev combineduseofcabozantinibandnivolumabinclinicalpractice AT kvmenshikov combineduseofcabozantinibandnivolumabinclinicalpractice AT shimusin combineduseofcabozantinibandnivolumabinclinicalpractice AT nisultanbaeva combineduseofcabozantinibandnivolumabinclinicalpractice AT evpopova combineduseofcabozantinibandnivolumabinclinicalpractice AT iamenshikova combineduseofcabozantinibandnivolumabinclinicalpractice |